CA2251256A1 - Spring-powered dispensing device for medical purposes - Google Patents
Spring-powered dispensing device for medical purposes Download PDFInfo
- Publication number
- CA2251256A1 CA2251256A1 CA002251256A CA2251256A CA2251256A1 CA 2251256 A1 CA2251256 A1 CA 2251256A1 CA 002251256 A CA002251256 A CA 002251256A CA 2251256 A CA2251256 A CA 2251256A CA 2251256 A1 CA2251256 A1 CA 2251256A1
- Authority
- CA
- Canada
- Prior art keywords
- latch means
- spring
- dispensing member
- movement
- latch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
- A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3117—Means preventing contamination of the medicament compartment of a syringe
- A61M2005/3118—Means preventing contamination of the medicament compartment of a syringe via the distal end of a syringe, i.e. syringe end for mounting a needle cannula
- A61M2005/312—Means preventing contamination of the medicament compartment of a syringe via the distal end of a syringe, i.e. syringe end for mounting a needle cannula comprising sealing means, e.g. severable caps, to be removed prior to injection by, e.g. tearing or twisting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum
Abstract
A dispensing device, such as a needleless injector, comprises a spring, which provides an energy store, and a dispensing member movable, to effect dispensing, under the force of the spring. A latch has a first position in which it restrains movement of the dispensing member and a second position in which it permits such movement. A trigger is operable by the user for moving the latch from the first position to the second position. A safety mechanism, preferably is the form of an appropriately shaped slot in the dispensing member, is effective before the device has been completely assembled to prevent movement of the latch to the second position.
Description
CA 022~12~6 1998-10-07 SPRIN~-POWERED DISPENSING OEVICE FOR MEDICAL PURPOSES
This invention relates to a dispensing device which engages a spring to urge a dispensing member to disperse, for example, a dose of liquid, powder, or a pellet. The spring may, for example, be a mechanical spring, such as of metal, or a compressed gas spring, such as of compressed air.
One example of such a dispensing device is a needleless injector. Needleless injectors of various types are described in, inter alia, International Patent Publications Nos. WO 93/03779 and WO 95/03844, which are in the name of the present applicant. The present invention will be described in detail with reference to a needleless injector, but it is to be understood that it applies to other types of spring powered dispensing device also.
In a spring powered needleless injector of the type described in the above International Patent Publications, the spring continuously exerts a force on a dispensing member, prior to use, and restraining means are provided for preventing the dispensing member moving under the force of the spring. The needleless injector is fired by, in effect, moving the injector into a condition in which the restraining means no longer have a restraining effect, thus permitting the dispensing member to move.
There is, however, a potential problem is assembling such devices, in that if the device is to be easily operable by the user, it may be easy, or at least possible, for the device to be accidentally fired during the process of manufacture. This is not only wasteful, but also poses a safety hazard to the personnel involved. It is an object of the present invention to provide means for overcoming this problem.
According to the present invention there is provided a device for dispensing a material or article, which comprises a spring, which provides an energy store, a dispensing member movable, to effect dispensing, under the CA 022~12~6 1998-10-07 WO9~/37705 PCT/GB97/00812 force of the spring, latch means having a first position in which it restrains movement of the dispensing member and a second position in which it permits such movement, trigger means operable by the user for moving the latch means from said first position to said second position, and a safety mechanism effective before the device has been completely assembled to prevent movement of the latch means to the second portion.
In a preferred embodiment of the invention, described in more detail below, the safety mechanism is incorporated into the latch member, which then has a safety position, in which it cannot be moved to its second position by the trigger means, and a non-safety position, in which it can be so moved.
The invention will now be further described with reference to the accompanying drawings, in which:
Figure 1 is a longitudinal section through an embodiment of a needleless injector according to the invention, and showing the injector prior to use, and with its latch in its safety position;
Figure la shows on a larger scale the latch used in Figure 1; and Figures 2a, 2b and 2c show diagrammatically part of the embodiment of Figures 1 and la, in three successive stages, namely with the latch in is safety position, with the latch in its non-safety position prior to firing, and with the latch in its position during firing.
In the embodiment of Figure 1, the injection force is provided by a compressed gas spring. This is in the form of a cylinder 130 which is closed at its upper end and which contains gas, typically air, under a pressure which is typically in the range 5.5 MPa (800 psi) to 20.7 MPa (3000 psi). The cylinder houses a ram 111. The end of the ram 111 has a frustoconical portion 131 and a flange 132 between which is situated an 0-ring seal 133. Prior to use, the ram 111 is held in the illustrated position by a CA 022~l2~6 l998-l0-07 latch 108 engaging in a groove in the ram, the upper surface of the groove forming a cam surface 109. The latch 108 is shown on a larger scale in Figure la. In the ~ position shown in Figure 1 the latch is unable to move leftwards, because it bears against the inner wall of a sleeve 102.
The lower end of the cylinder 130 has an outwardly directed flange 130a, which enables the cylinder to be held by crimping the flange 130a beneath an outwardly directed flange 140a at the upper end of a coupling 140. The sleeve 102 is formed of an upper sleeve portion 102a within which the cylinder is situated, and a lower sleeve portion 102b.
The sleeve portion 102b is connected to the coupling by the interengaging screw threads 141 formed on the inner and outer walls of the sleeve portion 102b and coupling 140 respectively.
The injector contains a medicament cartridge 103 which has a piston 104 slidingly and sealingly located therein, in contact with medicament 105. As considered from the upper end of Figure 1, the piston may comprise a cylindrical portion, a larger diameter cylindrical sealing portion, and a frusto-conical portion, for example as seen in Figure 1 of PCT/GB96/00551 referred to below. The cartridge 103 has a discharge orifice 106. The orifice 106 is sealed by a resilient seal 134 which is held in place by a seal carrier 135. The seal carrier 135 is connected to the lower sleeve portion 102b by a frangible joint 136.
As a precaution against accidental firing, a tear-off band 137 is provided as the lower part of the upper sleeve portion 102a. The lower edge of the tear-off band 137 bears against a ring 142 which is bonded to the exterior surface of the coupling 140 or (not shown) formed integrally therewith. The function of the ring is to prevent downward movement of the sleeve portion 102a relative to the coupling 140, for so long as the tear-off band 137 is present. Accordingly, the ring 142 need not extend completely around the periphery of the coupling, and CA 022~l2~6 l998-l0-07 could be replaced by one or more separate elements.
An annular space 138 is formed in the inside wall of the sleeve 102, where the sleeve is adjacent the cylinder 130, and the space is filled with a damping grease (indicated diagrammatically by a succession of black bands), so that the grease is in intimate contact both with the sleeve 102 and the cylinder 130. It should be noted that although a defined annular space is convenient from the point of view of providing a particular location for the grease, it could be omitted and the grease simply smeared over all or part of the outside of cylinder 130 and/or inside of sleeve 102.
When the embodiment of Figure 1 is to be operated, the user snaps off the seal carrier 135 at the frangible joint 136, which takes the seal 134 with it and exposes the orifice 106. The user then removes the tear-off band 137, and grasping the upper part of the sleeve 102 urges the orifice against the substrate (e.g. the user's own skin) which is to be injected. This moves the upper sleeve portion 102a downwardly, with respect to the lower sleeve portion 102b. This brings aperture 139 in the wall of the upper sleeve portion 102a into alignment with the latch 108, which is thus able to move sideways into the aperture under the influence of the force of the gas within the cylinder 130 acting on the latch via the cam surface 109 formed in the ram 111. The injector is thus caused to fire. As a precaution, in case the latch fails to move under the influence of the cam surface 109, an auxiliary cam surface 143 is provided on the inside of the sleeve portion 102a. The resulting recoil is damped by the damping grease.
By way of example only, the following are typical measurements for the embodiment of Figure 1:
CA 022~l2~6 l998-l0-07 s Diametrical clearance between gas cylinder outside diameter and sliding sleeve inside diameter 0.05mm Area of shear (i.e. cross section of grease) approximately 375mm2 Viscosity of grease 2.2 Kilopoise Momentum of ram at impact 0.06kg.m/s Mass of sleeve portion 102a 1.3g Mass of ram 2.5g Impact gap between ram and piston 4mm Gas pressure 6.2 MPa Bore of gas cylinder 5.0 mm While grease has been discussed as a preferred damping medium, similar results may be obtained by using air or oil damping devices - usually a cylinder and piston combination, i.e. a so-called "dashpot", wherein a fluid substance is caused to flow through a restriction, thereby to resist motion. Other viscous damping devices employ a vane, or a plurality of vanes, spinning in a damping medium, for example air, and these may be used if appropriate to the particular application. The effect and purpose of the damping grease is discussed in more detail in our copending International Application No.
PCT/GB96/00551.
It will be appreciated that it is important that needleless injectors, or indeed any injectors with power stored in them, should not be able to fire prematurely.
Once the above described device has been assembled this is achieved by the presence of the tear band 137, since until that is removed the device cannot fire. However, there is a potential problem in assembling the device, in that the penultimate component to be assembled is the upper sleeve portion 102a, which carries the tear band 137, (the last component to be assembled is the cartridge 103) and until the sleeve portion 102a is in place accidental firing is possible.
Accidental firing during the assembly process is a real possibility. Firstly, immediately prior to installation of the upper sleeve portion 102a there is a stage in which the partially assembled device has a period CA 022~12~6 1998-10-07 of quarantine to check for gas leaks. Secondly, during installation of the upper sleeve portion 102a the device will be subjected to numerous forces and vibration arising from the assembly equipment. Even after installation of the upper sleeve portion 102a, the assembly stresses arising as the cartridge is installed may be sufficient to cause accidental firing, despite the presence of the tear band 137.
To deal with this problem the device has a safety mechanism. In the illustrated embodiment this is provided by forming the slot in the ram not only with the cam surface 109 but also with a locking surface lO9a which extends perpendicular to the axis of the ram and is located radially inwardly of the cam surface 109. To enable the combination of cam surface 109 and locking surface lO9a to be used in the intended manner, the upper sleeve portion 102a is provided with an opening 144 which extends therethrough at a location which, prior to the device being fired, is aligned with the end of the latch 108 remote from the slot in the ram.
The way in which the safety mechanism operates can be seen from Figures 2a, 2b and 2c. When the latch and ram are initially assembled with one another, the latch occupies the position shown in Figure 2a, which is a safety position. Here, the ram-engaging latch portion 108a is acted on by the locking system lO9a. Friction forces ensure that the latch remains engaged with the locking surface; typically the ram exerts a force of at least 200N, so the latch is held in a vice-like grip.
Once the device has been assembled, preferably completely, and at least to the extent of the upper sleeve portion 102a being in place, it is cocked by inserting a tool through the opening 144 to push the latch in the direction of the arrow P in Figure 2 into the position shown in Figure 2b (and in Figure 1). In this position the ram-engaging latch portion 108a is in contact with the radially inner end of the ca~ surface 109. Accordingly, CA 022~12~6 1998-10-07 when the device is actuated as described above it is able to fire, and the latch moves to the position shown in Figure 2c.
This invention relates to a dispensing device which engages a spring to urge a dispensing member to disperse, for example, a dose of liquid, powder, or a pellet. The spring may, for example, be a mechanical spring, such as of metal, or a compressed gas spring, such as of compressed air.
One example of such a dispensing device is a needleless injector. Needleless injectors of various types are described in, inter alia, International Patent Publications Nos. WO 93/03779 and WO 95/03844, which are in the name of the present applicant. The present invention will be described in detail with reference to a needleless injector, but it is to be understood that it applies to other types of spring powered dispensing device also.
In a spring powered needleless injector of the type described in the above International Patent Publications, the spring continuously exerts a force on a dispensing member, prior to use, and restraining means are provided for preventing the dispensing member moving under the force of the spring. The needleless injector is fired by, in effect, moving the injector into a condition in which the restraining means no longer have a restraining effect, thus permitting the dispensing member to move.
There is, however, a potential problem is assembling such devices, in that if the device is to be easily operable by the user, it may be easy, or at least possible, for the device to be accidentally fired during the process of manufacture. This is not only wasteful, but also poses a safety hazard to the personnel involved. It is an object of the present invention to provide means for overcoming this problem.
According to the present invention there is provided a device for dispensing a material or article, which comprises a spring, which provides an energy store, a dispensing member movable, to effect dispensing, under the CA 022~12~6 1998-10-07 WO9~/37705 PCT/GB97/00812 force of the spring, latch means having a first position in which it restrains movement of the dispensing member and a second position in which it permits such movement, trigger means operable by the user for moving the latch means from said first position to said second position, and a safety mechanism effective before the device has been completely assembled to prevent movement of the latch means to the second portion.
In a preferred embodiment of the invention, described in more detail below, the safety mechanism is incorporated into the latch member, which then has a safety position, in which it cannot be moved to its second position by the trigger means, and a non-safety position, in which it can be so moved.
The invention will now be further described with reference to the accompanying drawings, in which:
Figure 1 is a longitudinal section through an embodiment of a needleless injector according to the invention, and showing the injector prior to use, and with its latch in its safety position;
Figure la shows on a larger scale the latch used in Figure 1; and Figures 2a, 2b and 2c show diagrammatically part of the embodiment of Figures 1 and la, in three successive stages, namely with the latch in is safety position, with the latch in its non-safety position prior to firing, and with the latch in its position during firing.
In the embodiment of Figure 1, the injection force is provided by a compressed gas spring. This is in the form of a cylinder 130 which is closed at its upper end and which contains gas, typically air, under a pressure which is typically in the range 5.5 MPa (800 psi) to 20.7 MPa (3000 psi). The cylinder houses a ram 111. The end of the ram 111 has a frustoconical portion 131 and a flange 132 between which is situated an 0-ring seal 133. Prior to use, the ram 111 is held in the illustrated position by a CA 022~l2~6 l998-l0-07 latch 108 engaging in a groove in the ram, the upper surface of the groove forming a cam surface 109. The latch 108 is shown on a larger scale in Figure la. In the ~ position shown in Figure 1 the latch is unable to move leftwards, because it bears against the inner wall of a sleeve 102.
The lower end of the cylinder 130 has an outwardly directed flange 130a, which enables the cylinder to be held by crimping the flange 130a beneath an outwardly directed flange 140a at the upper end of a coupling 140. The sleeve 102 is formed of an upper sleeve portion 102a within which the cylinder is situated, and a lower sleeve portion 102b.
The sleeve portion 102b is connected to the coupling by the interengaging screw threads 141 formed on the inner and outer walls of the sleeve portion 102b and coupling 140 respectively.
The injector contains a medicament cartridge 103 which has a piston 104 slidingly and sealingly located therein, in contact with medicament 105. As considered from the upper end of Figure 1, the piston may comprise a cylindrical portion, a larger diameter cylindrical sealing portion, and a frusto-conical portion, for example as seen in Figure 1 of PCT/GB96/00551 referred to below. The cartridge 103 has a discharge orifice 106. The orifice 106 is sealed by a resilient seal 134 which is held in place by a seal carrier 135. The seal carrier 135 is connected to the lower sleeve portion 102b by a frangible joint 136.
As a precaution against accidental firing, a tear-off band 137 is provided as the lower part of the upper sleeve portion 102a. The lower edge of the tear-off band 137 bears against a ring 142 which is bonded to the exterior surface of the coupling 140 or (not shown) formed integrally therewith. The function of the ring is to prevent downward movement of the sleeve portion 102a relative to the coupling 140, for so long as the tear-off band 137 is present. Accordingly, the ring 142 need not extend completely around the periphery of the coupling, and CA 022~l2~6 l998-l0-07 could be replaced by one or more separate elements.
An annular space 138 is formed in the inside wall of the sleeve 102, where the sleeve is adjacent the cylinder 130, and the space is filled with a damping grease (indicated diagrammatically by a succession of black bands), so that the grease is in intimate contact both with the sleeve 102 and the cylinder 130. It should be noted that although a defined annular space is convenient from the point of view of providing a particular location for the grease, it could be omitted and the grease simply smeared over all or part of the outside of cylinder 130 and/or inside of sleeve 102.
When the embodiment of Figure 1 is to be operated, the user snaps off the seal carrier 135 at the frangible joint 136, which takes the seal 134 with it and exposes the orifice 106. The user then removes the tear-off band 137, and grasping the upper part of the sleeve 102 urges the orifice against the substrate (e.g. the user's own skin) which is to be injected. This moves the upper sleeve portion 102a downwardly, with respect to the lower sleeve portion 102b. This brings aperture 139 in the wall of the upper sleeve portion 102a into alignment with the latch 108, which is thus able to move sideways into the aperture under the influence of the force of the gas within the cylinder 130 acting on the latch via the cam surface 109 formed in the ram 111. The injector is thus caused to fire. As a precaution, in case the latch fails to move under the influence of the cam surface 109, an auxiliary cam surface 143 is provided on the inside of the sleeve portion 102a. The resulting recoil is damped by the damping grease.
By way of example only, the following are typical measurements for the embodiment of Figure 1:
CA 022~l2~6 l998-l0-07 s Diametrical clearance between gas cylinder outside diameter and sliding sleeve inside diameter 0.05mm Area of shear (i.e. cross section of grease) approximately 375mm2 Viscosity of grease 2.2 Kilopoise Momentum of ram at impact 0.06kg.m/s Mass of sleeve portion 102a 1.3g Mass of ram 2.5g Impact gap between ram and piston 4mm Gas pressure 6.2 MPa Bore of gas cylinder 5.0 mm While grease has been discussed as a preferred damping medium, similar results may be obtained by using air or oil damping devices - usually a cylinder and piston combination, i.e. a so-called "dashpot", wherein a fluid substance is caused to flow through a restriction, thereby to resist motion. Other viscous damping devices employ a vane, or a plurality of vanes, spinning in a damping medium, for example air, and these may be used if appropriate to the particular application. The effect and purpose of the damping grease is discussed in more detail in our copending International Application No.
PCT/GB96/00551.
It will be appreciated that it is important that needleless injectors, or indeed any injectors with power stored in them, should not be able to fire prematurely.
Once the above described device has been assembled this is achieved by the presence of the tear band 137, since until that is removed the device cannot fire. However, there is a potential problem in assembling the device, in that the penultimate component to be assembled is the upper sleeve portion 102a, which carries the tear band 137, (the last component to be assembled is the cartridge 103) and until the sleeve portion 102a is in place accidental firing is possible.
Accidental firing during the assembly process is a real possibility. Firstly, immediately prior to installation of the upper sleeve portion 102a there is a stage in which the partially assembled device has a period CA 022~12~6 1998-10-07 of quarantine to check for gas leaks. Secondly, during installation of the upper sleeve portion 102a the device will be subjected to numerous forces and vibration arising from the assembly equipment. Even after installation of the upper sleeve portion 102a, the assembly stresses arising as the cartridge is installed may be sufficient to cause accidental firing, despite the presence of the tear band 137.
To deal with this problem the device has a safety mechanism. In the illustrated embodiment this is provided by forming the slot in the ram not only with the cam surface 109 but also with a locking surface lO9a which extends perpendicular to the axis of the ram and is located radially inwardly of the cam surface 109. To enable the combination of cam surface 109 and locking surface lO9a to be used in the intended manner, the upper sleeve portion 102a is provided with an opening 144 which extends therethrough at a location which, prior to the device being fired, is aligned with the end of the latch 108 remote from the slot in the ram.
The way in which the safety mechanism operates can be seen from Figures 2a, 2b and 2c. When the latch and ram are initially assembled with one another, the latch occupies the position shown in Figure 2a, which is a safety position. Here, the ram-engaging latch portion 108a is acted on by the locking system lO9a. Friction forces ensure that the latch remains engaged with the locking surface; typically the ram exerts a force of at least 200N, so the latch is held in a vice-like grip.
Once the device has been assembled, preferably completely, and at least to the extent of the upper sleeve portion 102a being in place, it is cocked by inserting a tool through the opening 144 to push the latch in the direction of the arrow P in Figure 2 into the position shown in Figure 2b (and in Figure 1). In this position the ram-engaging latch portion 108a is in contact with the radially inner end of the ca~ surface 109. Accordingly, CA 022~12~6 1998-10-07 when the device is actuated as described above it is able to fire, and the latch moves to the position shown in Figure 2c.
Claims (17)
1. An injector for dispensing a liquid, which comprises a spring, which provides an energy store, a dispensing member movable, to effect dispensing, under the force of the spring, latch means having a first position in which it restrains movement of the dispensing member and a second position in which it permits such movement, trigger means operable by the user for moving the latch means from said first position to said second position, and a safety mechanism effective before the device has been completely assembled to prevent movement of the latch means to said second position, wherein the safety mechanism is provided by a slot extending into the dispensing member from an exterior surface thereof, the slot being defined in part by a pair of latch-engaging surfaces, the latch means having a safety position in which it cannot be moved to the said second position by the trigger, in which it engages one of the surfaces, and engaging the other of the surfaces when in its said first position.
2. An injector according to claim 1, wherein the said one surface is substantially perpendicular to the intended direction of movement of the dispensing member, and the said other surface is inclined to the said direction of movement so that the movement of the dispensing member in the said direction exerts a force on the latch means, when the latch means is in its said first position, urging it towards its said second position.
3. An injector according to claim 1 or 2, having an outer casing surrounding the dispensing member and latch means, the outer casing having an aperture therethrough in the region of the latch means, the aperture providing access to permit insertion of a tool into the interior of the outer casing to move the latch means from its safety position to its said first position.
4. An injector according to any preceding claim, which is a needleless injector.
5. An injector according to claim 4, comprising a chamber containing a liquid to be injected and provided with an outlet orifice at one end thereof and a piston movable in the chamber to expel the said liquid through the outlet orifice, the dispensing member being spaced from the piston when the latch means is in its said first position and striking the piston to effect movement thereof when the latch means is moved to its said second position.
6. A device according to any preceding claim, wherein the spring is a gas spring.
7. A device according to any one of claims 1 to 5, wherein the spring is a mechanical spring.
8. A device for dispensing a material or article, which comprises a spring, which provides an energy store, a dispensing member movable, to effect dispensing, under the force of the spring, latch means having a first position in which it restrains movement of the dispensing member and a second position in which it permits such movement, trigger means operable by the user for moving the latch means from said first position to said second position, and a safety mechanism effective before the device has been completely assembled to prevent movement of the latch means to said second position.
9. A device according to claim 8, wherein the safety mechanism is provided by the latch means having a safety position in which it cannot be moved to the said second position by the trigger.
10. A device according to claim 9, wherein the dispensing member has a pair of latch-engaging surfaces formed therein, the latch means engaging one of the surfaces when in its safety position, and the other of its surfaces when in its said first position.
11. A device according to claim 10, wherein the dispensing member has a slot extending into it from an exterior surface thereof, the slot being defined in part by the said pair of surfaces.
12. A device according to claim 10 or 11, wherein the said one surface is substantially perpendicular to the intended direction of movement of the dispensing member, and the said other surface is inclined to the said direction of movement so that the movement of the dispensing member in the said direction exerts a force on the latch means, when the latch means is in its said first position, urging it towards its said second position.
13. A device according to any one of claims 9 to 12, having an outer casing surrounding the dispensing member and latch means, the outer casing having an aperture therethrough in the region of the latch means, the aperture providing access to permit insertion of a tool into the interior of the outer casing to move the latch means from its safety position to its said first position.
14. A device according to any one of claims 8 to 13, which is in the form of a needleless injector.
15. A device according to claim 14, comprising a chamber containing a liquid to be injected and provided with an outlet orifice at one end thereof and a piston movable in the chamber to expel the said liquid through the outlet orifice, the dispensing member being spaced from the piston when the latch means is in its said first position and striking the piston to effect movement thereof when the latch means is moved to its said second position.
16. A device according to any preceding claim, wherein the spring is a gas spring.
17. A device according to any one of claims 8 to 15, wherein the spring is a mechanical spring.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9607549.4A GB9607549D0 (en) | 1996-04-11 | 1996-04-11 | Spring-powered dispensing device |
GB9607549.4 | 1996-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2251256A1 true CA2251256A1 (en) | 1997-10-16 |
Family
ID=10791916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002251256A Abandoned CA2251256A1 (en) | 1996-04-11 | 1997-03-21 | Spring-powered dispensing device for medical purposes |
Country Status (27)
Country | Link |
---|---|
US (1) | US6135979A (en) |
EP (1) | EP0892648B1 (en) |
JP (1) | JP3450012B2 (en) |
KR (1) | KR20000005273A (en) |
CN (1) | CN1220613A (en) |
AT (1) | ATE231402T1 (en) |
AU (1) | AU716237B2 (en) |
BG (1) | BG102807A (en) |
BR (1) | BR9708767A (en) |
CA (1) | CA2251256A1 (en) |
CZ (1) | CZ326698A3 (en) |
DE (1) | DE69718631T2 (en) |
ES (1) | ES2191822T3 (en) |
GB (1) | GB9607549D0 (en) |
HU (1) | HUP9902139A3 (en) |
ID (1) | ID16590A (en) |
IL (1) | IL126356A0 (en) |
IS (1) | IS4859A (en) |
NO (1) | NO984720L (en) |
NZ (1) | NZ332232A (en) |
PL (1) | PL329187A1 (en) |
RU (1) | RU2171119C2 (en) |
SK (1) | SK139398A3 (en) |
TR (1) | TR199802021T2 (en) |
WO (1) | WO1997037705A1 (en) |
YU (1) | YU43598A (en) |
ZA (1) | ZA973011B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221347B2 (en) | 2004-12-01 | 2012-07-17 | Acushot, Inc. | Needle-free injector |
Families Citing this family (332)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US6264629B1 (en) | 1998-11-18 | 2001-07-24 | Bioject, Inc. | Single-use needle-less hypodermic jet injection apparatus and method |
US6383168B1 (en) | 1998-12-08 | 2002-05-07 | Bioject Medical Technologies Inc. | Needleless syringe with prefilled cartridge |
US6132395A (en) * | 1998-12-08 | 2000-10-17 | Bioject, Inc. | Needleless syringe with prefilled cartridge |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US7074210B2 (en) * | 1999-10-11 | 2006-07-11 | Felton International, Inc. | Universal protector cap with auto-disable features for needle-free injectors |
US6776776B2 (en) | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US6569123B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
US6770054B1 (en) | 1999-11-23 | 2004-08-03 | Felton International, Inc. | Injector assembly with driving means and locking means |
US7029457B2 (en) * | 1999-11-23 | 2006-04-18 | Felton International, Inc. | Jet injector with hand piece |
US6558348B2 (en) | 2000-04-07 | 2003-05-06 | Equidyne Systems, Inc. | Low cost disposable needleless injector system for variable and fixed dose applications |
WO2001087385A1 (en) | 2000-05-16 | 2001-11-22 | Weston Medical Limited | Liquid transfer device for drug reconstitution or liquid drug transfer |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
JP2002263106A (en) * | 2001-03-12 | 2002-09-17 | Olympus Optical Co Ltd | Optical probe device |
JP2004529754A (en) | 2001-03-14 | 2004-09-30 | ペンジェット・コーポレーション | System and method for removing dissolved gases from a solution |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US6613010B2 (en) | 2001-04-13 | 2003-09-02 | Penjet Corporation | Modular gas-pressured needle-less injector |
US6755220B2 (en) | 2001-04-27 | 2004-06-29 | Penjet Corporation | Method and apparatus for filling or refilling a needle-less injector |
US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US6824526B2 (en) | 2001-10-22 | 2004-11-30 | Penjet Corporation | Engine and diffuser for use with a needle-less injector |
GB0125506D0 (en) * | 2001-10-24 | 2001-12-12 | Weston Medical Ltd | Needle free injection method and apparatus |
GB0206560D0 (en) | 2002-03-20 | 2002-05-01 | Glaxo Group Ltd | Novel device |
MY139059A (en) | 2002-06-24 | 2009-08-28 | Alza Corp | Reusable, spring driven autoinjector |
MXPA05002072A (en) | 2002-08-26 | 2005-06-08 | Penjet Corp | Apparatus for needle-less injection with a degassed fluid. |
CN1833030B (en) | 2003-05-22 | 2014-07-23 | 美国弗劳恩霍夫股份有限公司 | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
AU2003270473A1 (en) | 2003-09-09 | 2005-04-27 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
DE10342058B4 (en) * | 2003-09-11 | 2007-10-25 | Tecpharma Licensing Ag | Administration device for an injectable product with a trigger safety device |
CN107090025A (en) | 2003-11-05 | 2017-08-25 | 达纳-法伯癌症研究所股份有限公司 | Stable alpha helical peptides and application thereof |
CA2546468C (en) | 2003-12-05 | 2015-05-26 | Aradigm Corporation | A device for readying a needle free injector for delivery |
US7717874B2 (en) | 2004-05-28 | 2010-05-18 | Bioject, Inc. | Needle-free injection system |
EP1781180A2 (en) * | 2004-07-08 | 2007-05-09 | CliniWave, Inc. | Rolling tube apparatus and method for treating a wound |
EP2181714A3 (en) | 2004-09-22 | 2010-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition for use in vaccination against staphylococcei |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US20090081253A1 (en) | 2005-03-23 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Composition |
MX2007012226A (en) | 2005-04-04 | 2007-12-10 | Univ Florida | Desferrithiocin polyether analogues. |
KR101446025B1 (en) | 2005-08-03 | 2014-10-01 | 아이바이오, 인크. | Compositions and methods for production of immunoglobulins |
US20070055199A1 (en) | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
TW201350129A (en) | 2005-12-22 | 2013-12-16 | Glaxosmithkline Biolog Sa | Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof |
KR20080106433A (en) | 2006-02-13 | 2008-12-05 | 프라운호퍼 유에스에이, 인코포레이티드 | Influenza antigens, vaccine compositions, and related methods |
US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
CA2647441C (en) | 2006-03-30 | 2021-02-23 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising staphylococcus aureus saccharides |
ES2776100T3 (en) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | System for targeted delivery of therapeutic agents |
JP5630998B2 (en) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | Polymers for functional particles |
ES2570334T3 (en) | 2006-06-02 | 2016-05-17 | Harvard College | Surface protein remodeling |
CN101466614B (en) * | 2006-06-13 | 2013-05-01 | 诺信公司 | Liquid dispensing syringe |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
DK2422810T3 (en) | 2006-07-17 | 2014-11-24 | Glaxosmithkline Biolog Sa | Influenza vaccine |
WO2008021367A2 (en) | 2006-08-11 | 2008-02-21 | President And Fellows Of Harvard College | Moenomycin biosynthesis-related compositions and methods of use thereof |
US7547293B2 (en) | 2006-10-06 | 2009-06-16 | Bioject, Inc. | Triggering mechanism for needle-free injector |
JO3598B1 (en) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
ES2397714T3 (en) | 2006-10-12 | 2013-03-08 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil-in-water emulsion adjuvant |
EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
MX2009005727A (en) | 2006-12-01 | 2009-08-27 | Anterios Inc | Amphiphilic entity nanoparticles. |
DK2474525T3 (en) | 2006-12-26 | 2020-07-13 | Lantheus Medical Imaging Inc | Ligands for imaging cardiac innervation |
EP2118123B1 (en) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
US7744563B2 (en) | 2007-02-23 | 2010-06-29 | Bioject, Inc. | Needle-free injection devices and drug delivery systems therefor |
US8324397B2 (en) | 2007-03-15 | 2012-12-04 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
JP5631201B2 (en) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Stitched polypeptide |
JP2010523595A (en) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | Poly (amino acid) targeting part |
US8778348B2 (en) | 2007-04-28 | 2014-07-15 | Ibio Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
DK2162230T3 (en) * | 2007-05-14 | 2011-02-07 | Shl Group Ab | Delivery Device |
US8524444B2 (en) | 2007-06-15 | 2013-09-03 | President And Fellows Of Harvard College | Methods and compositions for detections and modulating O-glycosylation |
AU2008267208B2 (en) | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
CA2692933C (en) | 2007-07-11 | 2016-10-18 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
EP2205074A4 (en) | 2007-10-04 | 2013-07-31 | Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
WO2009051837A2 (en) | 2007-10-12 | 2009-04-23 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
WO2009089119A2 (en) | 2008-01-03 | 2009-07-16 | Massachusetts Institute Of Technology | Decoy influenza therapies |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
CN102099052A (en) | 2008-04-16 | 2011-06-15 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine |
ES2604968T3 (en) | 2008-04-28 | 2017-03-10 | Zogenix, Inc. | New formulations for the treatment of migraine |
US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
DK2318832T3 (en) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated slides and related methods |
EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | Ligation of stapled polypeptides |
US9206223B2 (en) | 2008-09-22 | 2015-12-08 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US9974844B2 (en) | 2008-11-17 | 2018-05-22 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
EP2376619A4 (en) | 2008-12-15 | 2012-07-04 | Greenlight Biosciences Inc | Methods for control of flux in metabolic pathways |
DE102008063517A1 (en) * | 2008-12-18 | 2010-07-01 | Lts Lohmann Therapie-Systeme Ag | Disposable injector with a flexurally elastic housing II |
DE102008063519A1 (en) * | 2008-12-18 | 2010-07-01 | Lts Lohmann Therapie-Systeme Ag | Disposable injector with a flexurally elastic metal housing |
CA2744088A1 (en) | 2009-01-14 | 2010-07-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP2012525146A (en) | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Overcharged protein for cell penetration |
JP2012528858A (en) | 2009-06-01 | 2012-11-15 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | O-GlcNAc transferase inhibitor and use thereof |
US9163330B2 (en) | 2009-07-13 | 2015-10-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
GB2477487A (en) * | 2009-10-12 | 2011-08-10 | Owen Mumford Ltd | Injection device |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
GB0921295D0 (en) | 2009-12-04 | 2010-01-20 | Owen Mumford Ltd | Injection appaeratus |
CA2787940C (en) | 2010-01-27 | 2020-01-07 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
JP5827962B2 (en) | 2010-03-08 | 2015-12-02 | スローン ケタリング インスティテュート フォア キャンサー リサーチ | Cdc7 kinase inhibitors and uses thereof |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
CA2797786C (en) | 2010-05-07 | 2020-09-22 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through enzyme relocation |
KR101726471B1 (en) | 2010-05-11 | 2017-04-12 | 랜티우스 메디컬 이메징, 인크. | Compositions, methods and systems for the synthesis and use of imaging agents |
CA2799381A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
US9193989B2 (en) | 2010-06-18 | 2015-11-24 | Taiho Pharmaceutical Co., Ltd. | PRPK-TPRKB modulators and uses thereof |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK2603600T3 (en) | 2010-08-13 | 2019-03-04 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
JP6280367B2 (en) | 2010-08-31 | 2018-02-14 | グリーンライト バイオサイエンシーズ インコーポレーテッドGreenlight Biosciences,Inc. | A method for the control of fluxes in metabolic pathways via protease manipulation |
WO2012037268A2 (en) | 2010-09-15 | 2012-03-22 | Zogenix, Inc. | Needle-free injectors and design parameters thereof that optimize injection performance |
EP2640405A4 (en) | 2010-09-21 | 2015-04-15 | Massachusetts Inst Technology | Human-adapted ha polypeptides, vaccines, and influenza treatment |
WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
PL3590949T3 (en) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
SG189236A1 (en) | 2010-10-04 | 2013-05-31 | Massachusetts Inst Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
EP2438945A1 (en) * | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Reusable engine for an auto-injector |
JP2013545749A (en) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
MX347708B (en) | 2011-01-10 | 2017-05-09 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones. |
US20160199579A1 (en) * | 2011-01-10 | 2016-07-14 | Zogenix, Inc. | Needle free injectors |
ES2687494T3 (en) | 2011-01-19 | 2018-10-25 | Topokine Therapeutics, Inc. | Methods and compositions to reduce body fat |
BR112013018920A2 (en) | 2011-01-24 | 2017-11-28 | Anterios Inc | nanoparticle compositions, formulations thereof and their uses |
JP2014503586A (en) | 2011-01-24 | 2014-02-13 | アンテリオス, インコーポレイテッド | Oil composition |
CN109464393A (en) | 2011-01-24 | 2019-03-15 | 安特里奥公司 | Nanoparticulate compositions |
JP5794786B2 (en) * | 2011-02-04 | 2015-10-14 | 株式会社ダイセル | Needleless syringe |
EP3510998A1 (en) | 2011-03-03 | 2019-07-17 | Tersus Pharmaceuticals, LLC | Compositions and methods comprising c16:1n7-palmitoleate |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CA2834834A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
JP6027610B2 (en) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
DK2734510T3 (en) | 2011-07-22 | 2019-03-04 | Massachusetts Inst Technology | CLASS I-HISTONDEACETYLASES (HDAC) ACTIVATORS AND APPLICATIONS THEREOF |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP2014526250A (en) | 2011-09-09 | 2014-10-06 | グリーンライト バイオサイエンシーズ インコーポレーテッド | Cell-free preparation of carbapenem |
US9550000B2 (en) | 2011-09-09 | 2017-01-24 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
EP2755693A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
RS62993B1 (en) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
MX358886B (en) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Peptidomimetic macrocyles. |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
CN112500466B (en) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles |
AU2013221433B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
EP2850090B1 (en) | 2012-04-06 | 2018-10-03 | President and Fellows of Harvard College | Chemoenzymatic methods for synthesizing moenomycin analogs |
WO2013151697A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Methods and compounds for identifying glycosyltransferase inhibitors |
EP2834254A2 (en) | 2012-04-06 | 2015-02-11 | President and Fellows of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
WO2013163088A1 (en) | 2012-04-23 | 2013-10-31 | Zogenix, Inc. | Piston closures for drug delivery capsules |
WO2013169377A1 (en) | 2012-05-10 | 2013-11-14 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
BR112015004078B1 (en) * | 2012-08-30 | 2020-05-05 | Lts Lohmann Therapie Systeme Ag | test device for dispensing a substance in a medium |
CA2925035C (en) | 2012-09-26 | 2021-05-25 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
US20150225471A1 (en) | 2012-10-01 | 2015-08-13 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
LT2909204T (en) | 2012-10-12 | 2019-05-10 | The Broad Institute, Inc. | Gsk3 inhibitors and methods of use thereof |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
RS58023B2 (en) | 2012-11-01 | 2021-12-31 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
BR112015009470A2 (en) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | disubstituted amino acids and their methods of preparation and use |
WO2014071247A1 (en) | 2012-11-02 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors |
EP2922542A4 (en) | 2012-11-21 | 2016-10-05 | Topokine Therapeutics Inc | Methods and compositions for locally increasing body fat |
SI2922554T1 (en) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminally modified rna |
WO2014082065A1 (en) | 2012-11-26 | 2014-05-30 | President And Fellows Of Harvard College | Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof |
EP2742963A1 (en) * | 2012-12-17 | 2014-06-18 | Sanofi-Aventis Deutschland GmbH | Drug delivery device |
WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
UA118548C2 (en) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
CA2900008A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
WO2014124319A2 (en) | 2013-02-07 | 2014-08-14 | Massachusetts Institute Of Technology | Human adaptation of h5 influenza |
CN115804749A (en) | 2013-03-11 | 2023-03-17 | 度瑞公司 | Injectable controlled release compositions comprising high viscosity liquid carriers |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
BR112015022872A2 (en) | 2013-03-13 | 2017-11-07 | Harvard College | stapled and stitched polypeptides, their use, their method of preparation, their composition and amino acid |
US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CA2907915C (en) | 2013-04-03 | 2023-03-07 | Allertein Therapeutics, Llc | Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components |
WO2014165792A2 (en) | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
ES2774330T3 (en) | 2013-04-09 | 2020-07-20 | Massachusetts Inst Technology | Drug supply polymer and uses thereof |
US10301359B2 (en) | 2013-04-30 | 2019-05-28 | Massachusetts Institute Of Technology | Human adaptation of H3 influenza |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
EP3003309B1 (en) | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
AU2014278231B2 (en) | 2013-06-11 | 2017-05-25 | KALA BIO, Inc. | Urea derivatives and uses thereof |
US10227390B2 (en) | 2013-06-14 | 2019-03-12 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
RU2016105108A (en) | 2013-07-25 | 2017-08-30 | Дана-Фарбер Кэнсер Инститьют, Инк. | TRANSCRIPTION FACTOR INHIBITORS AND THEIR APPLICATION |
AU2014304545A1 (en) | 2013-08-05 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
CN105658807A (en) | 2013-08-05 | 2016-06-08 | 绿光生物科技股份有限公司 | Engineered proteins with protease cleavage site |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
PE20160685A1 (en) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9982009B2 (en) | 2013-10-15 | 2018-05-29 | Massachusetts Institute Of Technology | Methods for treating polycystic kidney disease and polycystic liver disease |
WO2015057958A2 (en) | 2013-10-16 | 2015-04-23 | Massachusetts Institute Of Technology | Enterobactin conjugates and uses thereof |
US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN106061261B (en) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | Crystal form of therapeutic compounds and application thereof |
CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
JP6494631B2 (en) | 2013-12-24 | 2019-04-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Colchistatin analogues and their synthesis and use |
WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
CA2940472A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
AU2015226911B2 (en) | 2014-03-07 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain |
MX2016012021A (en) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders. |
CN106415244B (en) | 2014-03-27 | 2020-04-24 | 中央研究院 | Reactive marker compounds and uses thereof |
JP6836400B2 (en) | 2014-03-28 | 2021-03-03 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | Breast and ovarian cancer vaccines |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
US10039816B2 (en) | 2014-04-30 | 2018-08-07 | Massachusetts Institute Of Technology | Siderophore-based immunization against gram-negative bacteria |
WO2015172686A1 (en) * | 2014-05-14 | 2015-11-19 | 苏州大学张家港工业技术研究院 | Pneumatic accumulating needleless syringe |
CN114805527A (en) | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | RAS inhibitory peptides and uses thereof |
CA2950440A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
JP6894239B2 (en) | 2014-05-27 | 2021-06-30 | アカデミア シニカAcademia Sinica | Compositions and methods for universal glycoforms for enhanced antibody efficacy |
CA2950415A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
JP6664338B2 (en) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Immunogenic combination |
MA40240B1 (en) | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Heteroaryl compounds of kinase inhibition |
WO2015200425A1 (en) | 2014-06-27 | 2015-12-30 | Topokine Therapeutics, Inc. | Topical dosage regimen |
EP3164379A1 (en) | 2014-07-02 | 2017-05-10 | Massachusetts Institute of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
US10736966B2 (en) | 2014-08-12 | 2020-08-11 | Massachusetts Institute Of Technology | Brush-poly (glycoamidoamine)-lipids and uses thereof |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
CN112245565A (en) | 2014-09-24 | 2021-01-22 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles and uses thereof |
SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
KR20210142781A (en) | 2014-10-21 | 2021-11-25 | 다케다 야쿠힌 고교 가부시키가이샤 | Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine |
CN107635979A (en) | 2014-10-27 | 2018-01-26 | 腾沙治疗公司 | Bromine domain inhibitor |
US20180015101A1 (en) | 2014-10-28 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for antigen-specific tolerance |
EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
WO2016086026A1 (en) | 2014-11-26 | 2016-06-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
EP3230272B1 (en) | 2014-12-10 | 2020-08-19 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
EP3237066B1 (en) | 2014-12-23 | 2020-10-21 | Sloan-Kettering Institute for Cancer Research | Polymorph of granaticin b |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
WO2016118191A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
WO2016160617A2 (en) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA2980172A1 (en) | 2015-03-30 | 2016-10-06 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
US10570104B2 (en) | 2015-04-27 | 2020-02-25 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
CN107848988B (en) | 2015-06-19 | 2021-10-22 | 麻省理工学院 | Alkenyl substituted 2, 5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP2018528217A (en) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
DK3350333T3 (en) | 2015-09-17 | 2022-01-31 | Modernatx Inc | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION |
ES2910425T3 (en) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compounds and compositions for the intracellular delivery of therapeutic agents |
EP3355882A1 (en) | 2015-10-01 | 2018-08-08 | Kythera Biopharmaceuticals, Inc. | Compositions comprising a statin for use in methods of adipolysis |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
SI3394030T1 (en) | 2015-12-22 | 2022-04-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
JP2019515876A (en) | 2016-03-08 | 2019-06-13 | アカデミア シニカAcademia Sinica | Methods for module synthesis of N-glycans and their arrays |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017176963A1 (en) | 2016-04-06 | 2017-10-12 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
MX2018014887A (en) | 2016-06-03 | 2019-06-06 | Sanofi Pasteur Inc | Modification of engineered influenza hemagglutinin polypeptides. |
US10105449B2 (en) | 2016-06-07 | 2018-10-23 | Massachusetts Institute Of Technology | Drug delivery polymers and uses thereof |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10792432B2 (en) | 2016-06-09 | 2020-10-06 | Becton, Dickinson And Company | Drive assembly and spacer for drug delivery system |
US10751476B2 (en) | 2016-06-09 | 2020-08-25 | Becton, Dickinson And Company | Actuator assembly for drug delivery system |
US10549044B2 (en) | 2016-06-09 | 2020-02-04 | Becton, Dickinson And Company | Spacer assembly for drug delivery system |
US10603445B2 (en) | 2016-06-09 | 2020-03-31 | Becton, Dickinson And Company | Needle actuator assembly for drug delivery system |
JP2019525901A (en) | 2016-06-14 | 2019-09-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Stabilized preparation of lipid nanoparticles |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
KR102467074B1 (en) | 2016-08-05 | 2022-11-11 | 사노피 파스퇴르 인코포레이티드 | Polyvalent pneumococcal polysaccharide-protein conjugate composition |
BR112019001971A2 (en) | 2016-08-05 | 2019-05-07 | Sanofi Pasteur, Inc. | multivalent pneumococcal polysaccharide-protein conjugate composition |
AU2017316663B2 (en) | 2016-08-22 | 2024-02-22 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
WO2018170306A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US20200129445A1 (en) | 2017-03-15 | 2020-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
EP4327876A2 (en) | 2017-06-23 | 2024-02-28 | Affinivax, Inc. | Immunogenic compositions |
WO2019013789A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds |
WO2019013790A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds and uses thereof |
CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
AU2018347405B2 (en) | 2017-10-11 | 2022-02-03 | Greenlight Biosciences, Inc. | Methods and compositions for nucleoside triphosphate and ribonucleic acid production |
JP7111809B2 (en) | 2017-10-16 | 2022-08-02 | ベクトン・ディキンソン・アンド・カンパニー | Spacer assembly for drug delivery device |
US11786477B2 (en) | 2017-12-01 | 2023-10-17 | North Carolina State University | Fibrin particles and methods of making the same |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
CN113271926A (en) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | Preparation of lipid nanoparticles and methods of administration thereof |
AU2020209167A1 (en) | 2019-01-16 | 2021-08-12 | Curza Global, Llc | Antimicrobial compounds and methods |
EP3911644A1 (en) | 2019-01-16 | 2021-11-24 | Curza Global LLC | Antimicrobial compounds and methods |
CA3128215A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020168466A1 (en) | 2019-02-19 | 2020-08-27 | Stemirna Therapeutics Co., Ltd. | Modified nucleoside and synthetic methods thereof |
US20220265803A1 (en) | 2019-07-31 | 2022-08-25 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
WO2021022173A1 (en) | 2019-07-31 | 2021-02-04 | Modernatx, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
CN115297930A (en) | 2019-11-13 | 2022-11-04 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
CA3169669A1 (en) | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
EP4238567A1 (en) | 2020-10-30 | 2023-09-06 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
EP4238979A1 (en) | 2020-10-30 | 2023-09-06 | Xeno-Interface Inc. | Beta-strand type crosslinked peptide |
AR124267A1 (en) | 2020-12-09 | 2023-03-01 | Genentech Inc | HIGH THROUGH METHODS FOR PREPARING LIPID NANOPARTICLES AND THEIR USES |
WO2022146931A1 (en) * | 2021-01-03 | 2022-07-07 | Fpin Llc | Damped autoinjectors |
EP4305088A1 (en) | 2021-03-09 | 2024-01-17 | Massachusetts Institute of Technology | Branched poly(-amino esters) for the delivery of nucleic acids |
TW202313065A (en) | 2021-05-28 | 2023-04-01 | 美商季卡尼醫療公司 | Compounds for treating genetic diseases |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
US20230233667A1 (en) | 2021-09-08 | 2023-07-27 | Affinivax, Inc. | Coronavirus vaccine |
CA3233926A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023114889A1 (en) | 2021-12-16 | 2023-06-22 | Modernatx, Inc. | Processes for preparing lipid nanoparticles |
WO2023129963A1 (en) | 2021-12-30 | 2023-07-06 | Curza Global, Llc | Antimicrobial compounds and methods |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023177579A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023193002A1 (en) | 2022-04-01 | 2023-10-05 | Modernatx, Inc. | Cross mixers for lipid nanoparticle production, and methods of operating the same |
WO2023235380A1 (en) | 2022-06-01 | 2023-12-07 | Zikani Therapeutics, Inc. | Macrolides for treating genetic diseases |
WO2023250513A1 (en) | 2022-06-24 | 2023-12-28 | Zikani Therapeutics, Inc. | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation |
WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
WO2024049994A1 (en) | 2022-09-01 | 2024-03-07 | Zikani Therapeutics, Inc. | Treatment of familial adenomatous polyopsis using a 13-membered macrolide |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR824357A (en) * | 1936-10-21 | 1938-02-07 | Method and devices for introducing gas and in particular compressed air into hypodermic and other ampoules and closing these ampoules | |
US2680439A (en) * | 1948-09-08 | 1954-06-08 | Arnold K Sutermeister | High-pressure injection device |
US2653602A (en) * | 1950-06-17 | 1953-09-29 | Becton Dickinson Co | Injection device |
US3217712A (en) * | 1963-01-22 | 1965-11-16 | Otto Konigslow Mfg Company | Ampoule applicator |
DE6944378U (en) * | 1969-11-14 | 1970-04-16 | Georg A Henke Gmbh Fa | SELF-INJECTING DEVICE |
US3945383A (en) * | 1974-08-08 | 1976-03-23 | Smithkline Corporation | Unit dose ampul for jet injector |
US4351692A (en) * | 1981-01-07 | 1982-09-28 | Ouellette Machinery Systems | Apparatus and method for automatically filling and heat weld sealing lengths of plastic tubing |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5026349A (en) * | 1988-10-05 | 1991-06-25 | Autoject Systems Inc. | Liquid medicament injector system |
US4902279A (en) * | 1988-10-05 | 1990-02-20 | Autoject Systems Inc. | Liquid medicament safety injector |
GB9118204D0 (en) * | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
US5681291A (en) * | 1992-11-19 | 1997-10-28 | Tebro S.A. | Disposable auto-injector for prefilled syringes |
CA2167586C (en) * | 1993-07-31 | 2005-01-25 | Terence Edward Weston | Needle-less injector |
GB9504878D0 (en) * | 1995-03-10 | 1995-04-26 | Weston Medical Ltd | Viscously coupled actuator |
US5865795A (en) * | 1996-02-29 | 1999-02-02 | Medi-Ject Corporation | Safety mechanism for injection devices |
-
1996
- 1996-04-11 GB GBGB9607549.4A patent/GB9607549D0/en active Pending
-
1997
- 1997-03-21 JP JP53593897A patent/JP3450012B2/en not_active Expired - Fee Related
- 1997-03-21 YU YU43598A patent/YU43598A/en unknown
- 1997-03-21 CN CN97195179A patent/CN1220613A/en active Pending
- 1997-03-21 ES ES97908414T patent/ES2191822T3/en not_active Expired - Lifetime
- 1997-03-21 RU RU98120409/14A patent/RU2171119C2/en active
- 1997-03-21 EP EP97908414A patent/EP0892648B1/en not_active Expired - Lifetime
- 1997-03-21 AU AU20387/97A patent/AU716237B2/en not_active Ceased
- 1997-03-21 BR BR9708767A patent/BR9708767A/en not_active Application Discontinuation
- 1997-03-21 WO PCT/GB1997/000812 patent/WO1997037705A1/en active IP Right Grant
- 1997-03-21 DE DE69718631T patent/DE69718631T2/en not_active Expired - Lifetime
- 1997-03-21 IL IL12635697A patent/IL126356A0/en unknown
- 1997-03-21 HU HU9902139A patent/HUP9902139A3/en unknown
- 1997-03-21 CA CA002251256A patent/CA2251256A1/en not_active Abandoned
- 1997-03-21 SK SK1393-98A patent/SK139398A3/en unknown
- 1997-03-21 NZ NZ332232A patent/NZ332232A/en unknown
- 1997-03-21 TR TR1998/02021T patent/TR199802021T2/en unknown
- 1997-03-21 PL PL97329187A patent/PL329187A1/en unknown
- 1997-03-21 KR KR1019980707976A patent/KR20000005273A/en not_active Application Discontinuation
- 1997-03-21 CZ CZ983266A patent/CZ326698A3/en unknown
- 1997-03-21 AT AT97908414T patent/ATE231402T1/en not_active IP Right Cessation
- 1997-04-09 ZA ZA9703011A patent/ZA973011B/en unknown
- 1997-04-10 ID IDP971186A patent/ID16590A/en unknown
-
1998
- 1998-09-29 BG BG102807A patent/BG102807A/en unknown
- 1998-10-06 IS IS4859A patent/IS4859A/en unknown
- 1998-10-09 NO NO984720A patent/NO984720L/en not_active Application Discontinuation
- 1998-10-09 US US09/178,991 patent/US6135979A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221347B2 (en) | 2004-12-01 | 2012-07-17 | Acushot, Inc. | Needle-free injector |
Also Published As
Publication number | Publication date |
---|---|
DE69718631D1 (en) | 2003-02-27 |
PL329187A1 (en) | 1999-03-15 |
RU2171119C2 (en) | 2001-07-27 |
NZ332232A (en) | 1999-08-30 |
AU2038797A (en) | 1997-10-29 |
BG102807A (en) | 1999-04-30 |
HUP9902139A2 (en) | 1999-11-29 |
ATE231402T1 (en) | 2003-02-15 |
JP3450012B2 (en) | 2003-09-22 |
TR199802021T2 (en) | 1999-01-18 |
ID16590A (en) | 1997-10-16 |
IL126356A0 (en) | 1999-05-09 |
CZ326698A3 (en) | 1999-04-14 |
US6135979A (en) | 2000-10-24 |
SK139398A3 (en) | 1999-03-12 |
HUP9902139A3 (en) | 2000-01-28 |
ES2191822T3 (en) | 2003-09-16 |
DE69718631T2 (en) | 2003-12-18 |
IS4859A (en) | 1998-10-06 |
EP0892648B1 (en) | 2003-01-22 |
CN1220613A (en) | 1999-06-23 |
NO984720D0 (en) | 1998-10-09 |
ZA973011B (en) | 1998-05-25 |
EP0892648A1 (en) | 1999-01-27 |
NO984720L (en) | 1998-10-09 |
WO1997037705A1 (en) | 1997-10-16 |
YU43598A (en) | 1999-09-27 |
GB9607549D0 (en) | 1996-06-12 |
BR9708767A (en) | 1999-08-03 |
KR20000005273A (en) | 2000-01-25 |
AU716237B2 (en) | 2000-02-24 |
JP2000508189A (en) | 2000-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6135979A (en) | Spring-powered dispensing device for medical purposes | |
RU2161511C2 (en) | Distribution device with spring drive | |
US9629960B2 (en) | Needleless injector | |
US4188856A (en) | Compressed-gas-actuated switching device | |
US5868713A (en) | Pneumatic retractable syringe | |
EP1053410B1 (en) | Gas spring device | |
US9138538B2 (en) | Device for readying a needle free injector for delivery | |
WO2011032731A1 (en) | Damping the piston rod for partially filled syringes | |
CN102317735A (en) | Cartridge for breaking rock | |
US5582010A (en) | Pyrotechnic device for the pressurization of a hydraulic circuit | |
RU2213599C1 (en) | Locking-trigger device | |
RU46939U1 (en) | LOCKING AND STARTING DEVICE | |
RU24106U1 (en) | LOCKING AND STARTING DEVICE | |
MXPA97006875A (en) | Assortment device operated by reso | |
DE2052983A1 (en) | Ignition device for rocket motors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |